In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease - Michal Geva; Ralf Reilmann; Robin Schubert; Kelly Chen; Y Paul Goldberg; Michael R. Hayden (Neurotherapeutics)